ストックスクリーナーアプリを入手
0.3768
4.92%
0.0033
アフターアワーズ：
.38
0.0032
+0.85%
前日終値:
$0.3801
開ける：
$0.3721
24時間の取引高:
17,378
Relative Volume:
0.09
時価総額：
$8.79M
収益：
$81.89M
当期純損益:
$-55.20M
株価収益率:
-0.1398
EPS:
-2.6959
ネットキャッシュフロー:
$-67.40M
1週間 パフォーマンス:
+2.62%
1か月 パフォーマンス:
-12.56%
6か月 パフォーマンス:
-42.82%
1年 パフォーマンス:
-91.24%
1日の値動き範囲:
$0.3702
$0.3995
1週間の範囲:
$0.3689
$0.4195
52週間の値動き範囲:
$0.365
$4.97
Turnstone Biologics Corp Stock (TSBX) Company Profile
名前
Turnstone Biologics Corp
セクター
電話
347-897-5988
住所
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
TSBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.3857 | 8.79M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.89 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.88 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-11-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-10-14 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-08-16 | 開始されました | SVB Securities | Market Perform |
| 2023-08-15 | 開始されました | BofA Securities | Buy |
| 2023-08-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Turnstone Biologics Corp (TSBX) 最新ニュース
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News
TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Turnstone Biologics to explore strategic alternatives - The Pharma Letter
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com
Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN
Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa
TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News
Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks
Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq
Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire
Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World
Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com
Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Turnstone Biologics stock downgraded amid concerns over therapy scalability and funding - Investing.com
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Turnstone Biologics Faces Financial and Operational Challenges - TipRanks
Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan
Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia
Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan
Warning: TSBX is at high risk of performing badly - MSN
Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World
BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com
Turnstone fires most staff in bid to to extend runway - The Pharma Letter
Turnstone Biologics Streamlines Operations and Leadership - Yahoo Finance
Turnstone Biologics announces strategic cuts and focus shift - Investing.com
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway - ForexTV.com
Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track - Fierce Biotech
Turnstone Biologics stock plunges to 52-week low of $0.45 - Investing.com
Turnstone Biologics Corp (TSBX) 財務データ
収益
当期純利益
現金流量
EPS
2.86%
0.29%
大文字化:
|
ボリューム (24 時間):